A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals

Pathobiology

Volumn 74, Issue 4, 2007, Pages 264-269

  Ponzoni, Maurilio ^a,c,d   Kwee, Ivo ^d,e   Mazzucchelli, Luca ^b,c,d   Ferreri, Andrés J M ^a,c,d   Zucca, Emanuele ^c,d   Doglioni, Claudio ^a,g   Cavalli, Franco ^c,d   Bertoni, Francesco ^c,d,f  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b INSTITUTE OF PATHOLOGY   (Switzerland)

^c International Extranodal Lymphoma Study Group   (Switzerland)

^d ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^e DALLE MOLLE INSTITUTE FOR ARTIFICIAL INTELLIGENCE IDSIA   (Switzerland)

^f Barts and the London   (United Kingdom)

^g Unit of Lymphoid Malignancies   (United Kingdom)

Author keywords

Biopsy; Brain tumor; Central nervous system; Lymphoma, primary; Non Hodgkin lymphoma; Tissue sampling; Virtual tissue bank

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CONTROLLED STUDY; HEALTH CARE FACILITY; HISTOPATHOLOGIC SKIN REACTION; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; INTERNET; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; HUMANS; IMMUNOCOMPETENCE; INFORMATION DISSEMINATION; INTERNET; LYMPHOMA; MIDDLE AGED; SOFTWARE; TISSUE BANKS;

EID: 34548070496     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104455     Document Type: Article

References (42)

1. Zucca E, Roggero E, Bertoni F, Cavalli F: Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997;8:727-737.
2. Zucca E, Roggero E, Bertoni F, Conconi A, Cavalli F: Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol 1999;10:1023-1033.
3. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F: Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266-272.
4. Lister A, Abrey LE, Sandlund JT: Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2002, pp 283-296.
5. Ferreri AJ, Abrey LE, Blay JY, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, Batchelor T: Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003;21:2407-2414.
6. Ferreri AJ, Dell Oro S, Reni M: Guidelines for the treatment of primary central nervous system lymphomas in immunocompetent patients. Forum (Genova) 2003;13:33-45.
7. Ferreri AJ, Dell'Oro S, Reni M, Foppoli M, Anzalone N, Govi S, Picozzi P, Truci G, Ponzoni M: Questions and answers in the management of primary central nervous system and ocular lymphomas. Haematologica 2003;88:1063-1068.
8. Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, Gubkin A, Calderoni A, Spina M, Brandes A, Ferrarese F, Rognone A, Govi S, Dell'Oro S, Locatelli M, Villa E, Reni M: Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004;90:353-358.
9. Ferreri AJ, Dell'Oro S, Foppoli M, Bernardi M, Brandes AA, Tosoni A, Montanari M, Balzarotti M, Spina M, Ilariucci F, Zaja F, Stelitano C, Bobbio F, Corazzelli G, Baldini L, Ponzoni M, Picozzi P, Caligaris Cappio F, Reni M: MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 2006;66:1435-1438.
10. Nakamura M, Shimada K, Ishida E, Konishi N: Histopathology, pathogenesis and molecular genetics in primary central nervous system lymphomas. Histol Histopathol 2004;19:211-219.
11. Shenkier TN, Blay JY, O'Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O'Brien P, Rubenstein J, Connors JM: Primary CNS lymphoma of T-cell origin: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group. J Clin Oncol 2005;23:2233-2239.
12. Ponzoni M, Terreni MR, Ciceri F, Ferreri AJ, Gerevini S, Anzalone N, Valle M, Pizzolito S, Arrigoni G: Primary brain CD30+ ALK1+ anaplastic large cell lymphoma ('ALKoma'): the first case with a combination of 'not common' variants. Ann Oncol 2002;13:1827-1832.
13. Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN, Harris NL, Batchelor TT: BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003;9:1063-1069.
14. Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphael M, Iraqi W, Sautes-Fridman C, Colombat P, Hoang-Xuan K, Martin A: A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006;107:190-196.
15. Rubenstein J, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M: Gene expression and angiotropism in primary CNS lymphoma. Blood 2006;107:3716-3723.
16. Cobbers JM, Wolter M, Reifenberger J, Ring GU, Jessen F, An HX, Niederacher D, Schmidt EE, Ichimura K, Floeth F, Kirsch L, Borchard F, Louis DN, Collins VP, Reifenberger G: Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol 1998;8:263-276.
17. Nakamura M, Sakaki T, Hashimoto H, Nakase H, Ishida E, Shimada K, Konishi N: Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas. Cancer Res 2001;61:6335-6339.
18. Rickert CH, Dockhorn-Dworniczak B, Simon R, Paulus W: Chromosomal imbalances in primary lymphomas of the central nervous system. Am J Pathol 1999;155:1445-1451.
19. Boonstra R, Koning A, Mastik M, Van Den Berg A, Poppema S: Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q. Virchows Arch 2003;443:164-169.
20. Sekita T, Tamaru JI, Isobe K, Harigaya K, Masuoka S, Katayama T, Kobayashi M, Mikata A: Diffuse large B cell lymphoma expressing the natural killer cell marker CD56. Pathol Int 1999;49:752-758.
21. Thompsett AR, Ellison DW, Stevenson FK, Zhu D: V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood 1999;94:1738-1746.
22. Montesinos-Rongen M, Kuppers R, Schluter D, Spieker T, Van Roost D, Schaller C, Reifenberger G, Wiestler OD, Deckert-Schluter M: Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 1999;155:2077-2086.
23. Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Deckert M: Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004;103:1869-1875.
24. Hickey WF: Basic principles of immunological surveillance of the normal central nervous system. Glia 2001;36:118-124.
25. Aloisi F: Immune function of microglia. Glia 2001;36:165-179.
26. Streilein JW: Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003;3:879-889.
27. Heppner FL, Prinz M, Aguzzi A: Pathogenesis of prion diseases: possible implications of microglial cells. Prog Brain Res 2001;132:737-750.
28. Ponzoni M, Berger F, Chassagne-Clement C, Tinguely M, Jouvet A, Iuzzolino P, Cerati M, Carbone A, Weis J, Motta T, Pedrinis E, Milani M, Orvieto E, Sanchez J, Blay JY, Ambrosetti A, Reni M, Vavassori V, Spina M, Calderoni A, Cortelazzo S, Conconi A, Zucca E, Aondio G, Ferrarese F, Gomez H, Ferreri AJM, Cavalli F, Borisch B: Reactive perivascular T-cell infiltrate is an independent favorable prognostic factor in primary central nervous system lymphomas (PCNSL) in immunocompetent patients. Ann Oncol 2002;13:79.
29. Riemersma SA, Jordanova ES, Schop RF, Philippo K, Looijenga LH, Schuuring E, Kluin PM: Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000;96:3569-3577.
30. Jordanova ES, Philippo K, Giphart MJ, Schuuring E, Kluin PM: Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma. Immunogenetics 2003;55:203-209.
31. Jordanova ES, Riemersma SA, Philippo K, Giphart-Gassler M, Schuuring E, Kluin PM: Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer 2002;35:38-48.
32. Riemersma SA, Oudejans JJ, Vonk MJ, Dreef EJ, Prins FA, Jansen PM, Vermeer MH, Blok P, Kibbelaar RE, Muris JJ, Schuuring EM, Kluin PM: High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. J Pathol 2005;206:328-336.
33. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT: Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003;101:815-821.
34. Anthony IC, Crawford DH, Bell JE: B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas. Brain 2003;126:1058-1067.
35. Ferreri AJ, Batchelor T, Zucca E, Cavalli F, Armitage J: International Collaborative Group against Primary CNS Lymphomas. J Clin Oncol 2003;21:1649-1650.
36. Oosterhuis JW, Coebergh JW, van Veen EB: Tumour banks: well-guarded treasures in the interest of patients. Nat Rev Cancer 2003;3:73-77.
37. Schilsky RL, Dressler LM, Bucci D, Monovich L, Jewell S, Suster S, Caligiuri MA, Kantoff PW, Compton C: Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. Clin Cancer Res 2002;8:943-948.
38. Malone T, Catalano PJ, O'Dwyer PJ, Giantonio B: High rate of consent to bank biologic samples for future research: the Eastern Cooperative Oncology Group experience. J Natl Cancer Inst 2002;94:769-771.
39. Hair JF, McNicol AM, Gusterson BA: Is research on human tissues at a crossroads? Eur J Cancer 2003;39:2253-2255.
40. Teodorovic I, Therasse P, Spatz A, Isabelle M, Oosterhuis W: Human tissue research: EORTC recommendations on its practical consequences. Eur J Cancer 2003;39:2256-2263.
41. Morente MM, Alonso S: Current challenges of human tumour banking. Hematol Oncol 2005;23:54-56.
42. van Veen EB, Riegman PH, Dinjens WN, Lam KH, Oomen MH, Spatz A, Mager R, Ratcliffe C, Knox K, Kerr D, van Damme B, van de Vijver M, van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Llombart Bosch A, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Passioukov A, Lejeune S, Therasse P, Oosterhuis JW: TuBaFrost 3: regulatory and ethical issues on the exchange of residual tissue for research across Europe. Eur J Cancer 2006;42:2914-2923.